Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Instrumentation

Carlyle Group takes a major stake in Unchained Labs

by Rick Mullin
April 30, 2021 | A version of this story appeared in Volume 99, Issue 16

The Carlyle Group has agreed to acquire a majority stake in Unchained Labs, a life sciences instrumentation company focused on biologics and gene therapy research, for $435 million. Unchained, which supplies tools for analyzing and characterizing complex large molecules, has 170 employees and expects to generate over $75 million in revenue this year. Its products include Uncle, a protein analysis instrument for gene therapy research that combines fluorescence, static light scattering, and dynamic light scattering measurement modes.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.